Product Description: Palbocent (Palbociclib) is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
- an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
- fulvestrant in women with disease progression following endocrine therapy.
|Available Pack Size||:||21’s Pot|
Manufacturer: Incepta Pharmaceuticals Ltd